BJBai Ji

Bai Ji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bai Ji has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Mingda Han

    State Key Laboratory of Inorganic Synthesis and Preparative Chemistry College of Chemistry Jilin University Changchun China

    2 shared publications
  • Qiannan Miao

    State Key Laboratory of Inorganic Synthesis and Preparative Chemistry College of Chemistry Jilin University Changchun China

    2 shared publications
  • Xiaocheng Li

    Department of Hepatobiliary and Pancreatic Surgery General Surgery Center The First Hospital of Jilin University Changchun China

    2 shared publications
  • Bingru Shao

    State Key Laboratory of Inorganic Synthesis and Preparative Chemistry College of Chemistry Jilin University 2699 Qianjin Street Changchun 130012 China

    1 shared publication
  • Changzheng Li

    Department of Hepatobiliary and Pancreatic Surgery General Surgery Center The First Hospital of Jilin University Changchun China

    1 shared publication
  • Dan Zhou

    Department of Hepatobiliary and Pancreatic Surgery General Surgery Center The First Hospital of Jilin University 71 Xinmin Street Changchun 130021 China

    1 shared publication

Latest Publications

  • Open Access

    A Defect‐Engineered Sono‐Piezocatalytic In Situ Hydrogel for Preventing Hepatocellular Carcinoma Recurrence After Incomplete Radiofrequency Ablation

    by Jianji Ke, Feiqi Liu, Changzheng Li, Ying Yan, Xiuan Li, Mingda Han, Qiannan Miao, Xiaocheng Li, Bai Ji, Fei Yan

    Residual tumor cells and the immunosuppressive microenvironment caused by incomplete radiofrequency ablation (iRFA) lead to hepatocellular carcinoma (HCC) recurrence. In this study, HA‐V‐MTO/LMP@Gel, an injectable sono‐piezocatalytic hydrogel, is developed for local treatment of HCC after iRFA. It combines hyaluronic acid‐modified, oxygen vacancy‐engineered Mn–Ti metal–organic framework nanosheets (HA‐V‐MTO) with reactive oxygen species (ROS)‐responsive liposomes co‐loaded with STING agonist MSA‐2 and an anti‐PD‐1 antibody (LMP) within a thermosensitive chitosan/β‐glycerophosphate (CS/β‐GP) hydrogel. Oxygen‐vacancy engineering lowers the O 2 adsorption energy from 0.187 to −2.559 eV and raises the piezoelectric coefficient d 33 from 35.36 to 108.73 pm V −1 . Under ultrasound, HA‐V‐MTO generates ROS through sono‐piezocatalysis, with an additional Fenton‐like reaction from the Mn‐containing framework. The resulting oxidative stress induces mitochondrial injury and promotes cytosolic mtDNA release, thereby facilitating cGAS‐mediated STING activation. ROS‐mediated LMP destabilization releases MSA‐2, which further enhances STING signaling. The hydrogel undergoes temperature‐triggered gelation for sustained local release. In a post‐iRFA model, HA‐V‐MTO/LMP@Gel + US raises intratumoral IFN‐β 7.9‐fold, increases the proportion of mature dendritic cells to 50.8% and that of intratumoral CD8 + T cells to 26.5%, suppresses residual regrowth, prolongs survival, and protects against tumor rechallenge. This work presents a locally retained sono‐piezocatalytic system that couples tumor killing with STING‐driven immune activation after iRFA.

  • Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano‐Epidrug Effects on Immune Modulation and Antigenicity Restoration

    by Xiaocheng Li, Yahui Liu, Jianji Ke, Zhihua Wang, Mingda Han, Ning Wang, Qiannan Miao, Bingru Shao, Dan Zhou, Fei Yan, et al.

    Radiofrequency ablation (RFA), a critical therapy for hepatocellular carcinoma (HCC), carries a significant risk of recurrence and metastasis, particularly owing to mechanisms involving immune evasion and antigen downregulation via epigenetic modifications. This study introduces a “nano‐epidrug” named MFMP. MFMP, which is composed of hollow mesoporous manganese dioxide (MnO2) nanoparticles, FIDAS‐5 as an MAT2A inhibitor, macrophage membrane, and anti‐PD‐L1 (aPD‐L1), targets HCC cells. By selectively binding to these cells, MFMP initially reverses immune suppression via PD‐L1 inhibition. After endocytosis, MFMP disassembles in the tumor microenvironment, releasing FIDAS‐5 and Mn2+. FIDAS‐5 prevents cGAS methylation, whereas Mn2+ aids STING pathway restoration. In addition, FIDAS‐5 reduces m6A RNA modification, suppressing EGFR expression. These changes enhance HCC antigenicity to promote cytotoxic T cell recognition and cytotoxic killing. Furthermore, MFMP mediates immunogenic cell death in HCC by synergizing with RFA through cGAS DNA demethylation, EGFR mRNA demethylation, and TBK1 protein phosphorylation, thereby inhibiting recurrence and metastasis and enhancing immune memory. Thus, MFMP is a potential adjunctive therapy requiring clinical validation.